The Global Fund Board cancels Round 11 and introduces tough new rules for grant renewals

Financial difficulties have caused the Global Fund Board to cancel Round 11. This difficult decision was made at a stressful two-day Board meeting just concluded in Accra, Ghana. The Board also announced new rules for grant renewals in an attempt to find savings that can be applied to funding new proposals.

Read More →

No political will to support generic medication

South African health experts are calling on governments to use legally available mechanisms to promote the production or import of generic drugs in their countries.

Read More →

Time of great change in TB drug development

We are living in a time of great change and excitement in TB drug development. The last year has witnessed a number of epochal changes, including the approval and rollout of the most rapid test for TB ever discovered, the GeneXpert; the combination TB drug studies in the relapse mouse model of Eric Nuermberger and Jacques Grosset at Johns Hopkins with support from the TB Alliance; the progression of TMC207 into late phase II and of OPC67683 into phase III; and the first new regimen EBA study, NC-001 also from the Alliance.

Read More →

November: Month of action on TB and maternal and child health

Target TB has joined up with the White Ribbon Alliance for Safe Motherhood (WRA) to raise awareness about the impact of tuberculosis (TB) on maternal and child health.

Read More →

New TB roadmap emphasizes critical role of research

“Elimination of tuberculosis (TB) is more than an aspiration. We know it could become a reality, but this will happen only if we achieve radical transformation in the way TB is diagnosed, treated and prevented. This goal can be realized only if TB research is intensified and envisioned in an entirely new way.” These are the first words of Lucica Ditiu, Executive Secretary of Stop TB Partnership, in the International Roadmap of Tuberculosis Research, launched this weekend in Lille.

Read More →

ZAMSTAR project reduces prevalence of tuberculosis by 22%

The results of a large-scale community-randomized trial, which were presented at the 42nd World Conference on Lung Health in Lille, France show that the Zambia South Africa TB and AIDS Reduction (ZAMSTAR) study's "Household Counselling" intervention reduced the prevalence of culture positive tuberculosis by 22% compared to the communities that did not receive the intervention.

Read More →

Out of the Dark: An implementers’ guide to managing TB in children

This report outlines the current state of paediatric TB care, looking at current practices, new developments and research needs – in paediatric TB diagnosis, treatment and prevention.

Read More →

Funding for TB research and development was flat in 2010 compared to 2009

New data released by the Treatment Action Group (TAG) and the Stop TB Partnership finds that in 2010 the world spent just $617 million in tuberculosis (TB) research and development (R&D), or 0.3% less than 2009 funding levels - the first time TAG documents no growth since it began tracking TB research investments in 2005.

Read More →

WHO recommendations on Interferon-Gamma Release Assays

WHO's Stop TB Department has published new recommendations related to the use of TB Interferon-Gamma Release Assays (IGRAs) as a replacement of the tuberculin skin test (TST) to detect latent TB in low- and middle-income countries (the recommendations are not intended for high-income countries or to supersede existing national guidelines in these countries).

Read More →

Time for zero deaths from tuberculosis

Five renowned AIDS and TB activists and public health experts have written an editorial in *The Lancet* welcoming the leadership of Lucica Ditiu of Stop TB. They also call for more vocal leadership from all organisations working to end the TB epidemic. They also say that we need an aspirational goal to galvanise the struggle against TB: TB is treatable and therefore we should aim to have no deaths from the disease. Time for zero deaths from tuberculosis -------------------------------------- Source: [The Lancet, Volume 378, Issue 9801, Pages 1449 - 1450, 22 October 2011]( Salmaan Keshavjee (a), Mark Harrington (b), Gregg Gonsalves (a), Lucy Chesire (c), Paul E Farmer (a) When Robert Koch presented his discovery of the tuberculosis bacillus in March, 1882, he hoped it would lead to the eradication of “this terrible plague of mankind”.[1] More than a century later, tuberculosis remains a leading killer of adults: of about 9.4 million people newly infected with tuberculosis each year, 3.5 million are undiagnosed and continue to transmit the disease and more than 1.7 million die. Tuberculosis is the main killer of people with HIV infection; drug-resistant strains continue to spread; and paediatric tuberculosis remains an area of neglect. [2, 3] In the past decade, the number of new cases of tuberculosis worldwide has barely declined, and the number of deaths remains catastrophic: more than 4,500 per day for this largely treatable disease. As aLancet editorial pointed out, “A status quo in tuberculosis control is unacceptable.”[4] This status quo is not inevitable. A logical place to look for fresh leadership and vision is the Stop TB Partnership. Created in 2001 as a network of international organisations, countries, technical agencies, and donors, the Partnership was tasked with ensuring that every patient with tuberculosis has access to effective diagnosis and treatment. In its first decade, however, the Stop TB Partnership—housed at WHO headquarters in Geneva—seems to have operated essentially as a subsidiary of WHO's Tuberculosis Department with the majority of funds going to WHO's Tuberculosis Department, rather than external partners. [5, 6] But this situation may yet change. The newly appointed Executive Secretary of the Partnership, Lucica Ditiu, has initiated steps to address potential financial and administrative conflicts of interest in the Stop TB Partnership's relation with WHO. More importantly, Ditiu has called for a bold new vision in the struggle against tuberculosis. She and her team have started a campaign to prevent a million deaths among patients co-infected with HIV and tuberculosis. [7] She should be congratulated for these steps and supported in her efforts by her Board, the WHO Director-General, governments of countries with a high-burden of tuberculosis, and the tuberculosis community. Transforming the Partnership into an effective, independent, and transparent body capable of acting as a locus for innovative thinking is a crucial step in recasting the global struggle against tuberculosis. Changing the tenor of advocacy around tuberculosis is another important step. Without the networks of grassroots health activists and civil society institutions that define the HIV/AIDS movement, the global tuberculosis community has been unable to successfully scale-up patient-centred approaches to care, or hold governments and key international bodies (including funders) to account with regard to their commitments to tackle this disease. The health-activist community must take urgent steps to remedy this. Investment in tuberculosis-specific efforts of existing HIV/AIDS and civil society organisations—building on such efforts in Brazil, Kenya, India, South Africa, Uganda, and Zambia—or groups working on related social issues would be a start. Much would be achieved if leaders of global health initiatives—the Global Fund to Fight AIDS, Tuberculosis and Malaria, the US President's Emergency Plan For AIDS Relief, the US Global Health Initiative, and UNICEF—became more vocal in their demand for better tuberculosis outcomes and innovative approaches to stemming the disease. These organisations have the capacity to bring key stakeholders to the table: the diagnostic and pharmaceutical industries; partners addressing social antecedents to tuberculosis (for example poverty, discrimination, and detention); those who provide treatment of tuberculosis comorbidities (HIV and diabetes); and, in many settings, private providers of tuberculosis diagnosis and care. Most vitally, an aspirational goal must define the struggle ahead. [8] Effective treatment for tuberculosis has been available since the 1940s, and there is little reason for large numbers of people to be dying from this disease. [9] New diagnostics and treatment approaches are needed—especially for children, patients co-infected with HIV, those with extra-pulmonary disease, and patients with multidrug-resistant and extensively drug-resistant tuberculosis. But even today, when appropriate and tailored programmes have been put in place, a clear movement towards zero deaths has been observed in places as daunting as the prisons of Tomsk, Russia—where previously as many as a quarter of all patients had died. [10] Therefore, as UNAIDS and UNICEF embark on their own campaigns for zero deaths, [11, 12] it is critical that the tuberculosis community as a whole aspires to the same demonstrably achievable goal, and works in solidarity to accomplish it. *SK has chaired and participated in the Green Light committee at the Stop TB Partnership and WHO, is a member of the MDR-TB working group at the Stop TB Partnership, and has received research funding from the Eli Lilly Foundation. MH is director of Treatment Action Group, has been a member of WHO's Strategic Advisory Group for Tuberculosis, and has been involved in working groups with the Stop TB Partnership. LC is director of the TB ACTION group in Kenya, has participated in working groups at the Stop TB Partnership, is a member of WHO's Strategic Advisory Group for Tuberculosis, and an alternate member of the communities delegation to the board of the Global Fund to Fight AIDS, Tuberculosis and Malaria. GG and PF declare that they have no conflicts of interest.* References ---------- 1 Koch R. Die aetiologie der tuberculose, a translation by Berna Pinner and Max Pinner with an introduction by Allen K Krause. Am Rev Tuberc 1932; 25: 285-323. 2 Lönnroth K, Castro KG, Chakayah JM, et al. Tuberculosis control and elimination 2010—50: cure, care, and social development.Lancet 2010; 375: 1814-1829. 3 Keshavjee S, Farmer PE. Picking up the pace—scale-up of MDR tuberculosis treatment programs. N Engl J Med 2010; 369: 1781-1784. 4 The Lancet. A new era for global tuberculosis control?. Lancet 2011; 378: 2. 5 Treatment Action Group (TAG). Steps being taken by the Coordinating Board to reduce conflict of interest and improve transparency in the Stop TB Partnership. (accessed Sept 10, 2011). 6 Stop TB Partnership Secretariat Financial Management Report Summary Statement of Income and Expenditure for the year ending 31 December 2010. Expenditures. March, 2011. Washington DC, p 6. (accessed Sept 29, 2011). 7 Stop TB Partnership/World Health Organization. Time to act: save a million lives by 2015. Prevent and treat tuberculosis among people living with HIV. Geneva: World Health Organization, 2011. (accessed Sept 26, 2011). 8 Castro KG, LoBue P. Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globally. Emerg Infect Dis 2011; 17: 337-342. 9 Dye C, Williams BG. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 2008; 5: 653-662. 10 Keshavjee S, Gelmanova I, Pasechnikov A, et al. Treating multi-drug resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann N Y Acad Sci 2008; 1136: 1-11. 11 UNICEF. Believe in zero—achieving zero. (accessed Sept 26, 2011). 12 UNAIDS. UNAIDS: 2011—2015 Strategy. Getting to zero. Geneva: UNAIDS, 2010. Sept 26, 2011).
a Program in Infectious Disease and Social Change, Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA b Treatment Action Group, New York, NY, USA c TB ACTION Group, Nairobi, Kenya

Read More →

Page 79 of 81 · Total posts: 10

←First 78 79 80 Last→

To subscribe to the Weekly Newsletter of new posts, enter your email here:

Learn About TB